Email Medtest Medtest Headquarters Medtest Facebook Medtest Linkedin

MedTest Holdings Announces a New Chief Financial Officer

Jun 15, 2016 - press releases

For Immediate Release: (Canton, Michigan)  Effective June 12, 2016, Davina Chow has been appointed as the new Chief Financial Officer (CFO) by MedTest Holdings replacing Tim Allen effective June 10, 2016. 

Davina brings 20 years of financial leadership experience with multinational publicly traded companies in the diagnostics industry. Prior to joining MedTest, Davina held the Controller position at Siemens Healthcare, as well as having held key leadership roles within its predecessors which include Dade Behring Canada, Behring Diagnostics Canada and Syva Canada. Most recently, Davina was part of the Business Optimization Team at Victorian Order of Nurses, where she optimized financial and SAP FICO processes. Davina holds a Bachelor of Commerce degree in Accounting and Finance from Concordia University in Montreal, Quebec and is a Certified Management Accountant, member of Chartered Professional Accountants of Canada.

Hanjoon Ryu, CEO of MedTest, stated: “Davina’s strong focus on our customers and her extensive experience in the in-vitro diagnostic industry enables her to lead MedTest through today’s challenging market and to strengthen our competitiveness for the future.  I want to express my sincere gratitude to Tim Allen for his numerous contributions and wish him the best of luck in his new adventure.”

About MedTest:  MedTest is a diagnostics company that provides automated, fast, and cost effective blood and urine testing solutions for diabetes, cardiovascular disease, drugs of abuse, pain management and wellness testing.  In June 2013, MedTest acquired Pointe Scientific, a US-based company that has been developing, manufacturing and distributing clinical diagnostic products including clinical chemistry reagents and instruments in the United States and internationally since 1981.  In October 2014, MedTest acquired Clinitox Diagnostix, a Canadian-based company, which provides drugs of abuse confirmatory testing capabilities via liquid chromatography/mass spectrophotometry (LC/MS) instrumentation and associated reagents and consumables as pre-packaged kits.  Implementation consulting provides the customer with on-site assistance in setting up their LC/MS testing and developing the standard operating procedures enabling the laboratory to initiate testing sooner and reduce costly start-up costs.

For additional information, please contact:

MedTest
Debbie Whitehair, MT(ASCP)SC
Vice President, Marketing
484-748-1603
dwhitehair@medtest.com
www.medtest.com

                                                              

PR-M3111-06   06/16

Job Opening: Key Accounts Manager

Jun 9, 2016 - news

MedTest: A Great Place To Work

Position:

Key Accounts Manager - Northeast or Mid-Atlantic Territory

Type:

Full Time

Duties

  • Direct the company’s overall sales strategy in your assigned territory to achieve that territories sales goals

  • Create sales strategies that are in alignment with the company’s strategic imperatives

  • Develop and manage both direct and channel partner opportunities

  • Identify areas of opportunity within the assigned territory to further develop prospect opportunities

  • Collaborate with the Vice President of North American Sales, Business Development Manager, and Key Account Managers from other territories

  • As the key contact for GPO and IDN opportunity development, you will grow and manage these opportunities  

Candidate

  • Four year college degree required. Majors in Marketing, Business Administration, or Communication preferred.

  • Minimum of five years in sales leadership working with channel partners in the medical device market, or in complex selling situations such as IDN, Multi-Site Sales, and/or Corporate Accounts

  • Diverse experience in sales, management, marketing and executive leadership in the medical device distribution industry

  • Strong leadership and consensus building skills

  • Marketing management and strategic planning experience

  • A proven track record in developing and administering a marketing program

  • Excellent written and oral communication skills required

  • Professional and dynamic presentation and interpersonal skills

  • Firm knowledge of Microsoft Office and Windows based applications

  • Must be willing to travel up to 60 - 70% of the time, based on customer and business demands

 

Please submit your resume or CV (Curriculum Vitae) and cover letter with salary requirements to marketing@medtest.com

MedTest Announces Availability of a Hydrocodone Assay for Urine Drug Screening

Jun 1, 2016 - press releases

(Canton, Michigan)  MedTest announced today the availability of a hydrocodone assay for use as an open-channel reagent or for use on the BS-200 and BS-480 Chemistry Analyzers for urine drug screening.  The addition of hydrocodone broadens MedTest’s menu of urine drug screening reagents already available. 

Hydrocodone is a semi-synthetic opioid derived from codeine and thebaine. It is used to relieve moderate to severe pain and to treat a cough. Hydrocodone is prescribed predominantly in the United States. Commercial Hydrocodone preparations are often combined with another medication to increase efficacy and reduce adverse effects. It is available as combination drugs with Acetaminophen such as Vicodin and Lortab, Ibuprofen (Vicoprofen) and antihistamines (Hyconine).  In recent years, an increase in the abuse of the prescription pain management drugs Hydrocodone and Hydromorphone has been observed. Hydrocodone is rapidly metabolized to Hydromorphone and its glucuronide, and can be found in human urine for up to 2-3 days.

Hanjoon Ryu, CEO of MedTest, stated: “Hydrocodone is rapidly metabolized to hydromorphone and its glucuronide.  Since it does not metabolize into morphine, standard opiate testing reagents will not detect its presence.  Physicians request the hydrocodone test to effectively manage their patients and insure that they are getting a total picture of the patient’s medication status.  Adding hydrocodone to our broad menu of urine drugs of abuse reagents is of value to the physician.”

About MedTest:  MedTest is a diagnostics company that provides automated, fast, and cost effective blood and urine testing solutions for diabetes, cardiovascular disease, drugs of abuse, pain management and wellness testing.  In June 2013, MedTest acquired Pointe Scientific, a company that has been developing, manufacturing and distributing clinical diagnostic products including clinical chemistry reagents and instruments in the United States and internationally since 1981.  In the fall of 2014, MedTest acquired Clinitox Diagnostix, a company that manufactures and supports drug confirmatory testing via Liquid Chromatography/Mass Spectrometry (LC/MS).

For additional information:

MedTest
Debbie Whitehair, MT(ASCP)SC
Vice President, Marketing
484.748.1603
dwhitehair@medtest.com
www.medtest.com

 

PR-D2111-01   04/16

Inside MedTest - Spring 2016 Newsletter

Apr 26, 2016 - news

See what's going on at MedTest!

MedTest Spring 2016 Domestic Newsletter

MedTest Announces Availability of a 25-OH Vitamin D Assay for the BS-480 Chemistry Analyzer

Apr 21, 2016 - press releases

(Canton, Michigan)  MedTest announced today the availability of a 25-OH Vitamin D Assay for the BS-480 Chemistry Analyzer.  MedTest is the exclusive US distributor of the BS-480 Chemistry Analyzer including manufacturing and distribution of reagents, calibrators and quality control products for the general chemistry and drugs of abuse testing markets in the United States and Canada.  Addition of a Vitamin D assay to the BS-480 Analyzer broadens the extensive menu with drugs of abuse reagents for urine drug screening, a full menu of chemistry tests and specialty tests like HbA1c and Lp(a).

The Vitamin D assay is simple to add and simple to run on the BS-480 analyzer.  Reagents are liquid, ready to use. Total automation eliminates manual sample pretreatment steps.  Results from serum, heparinized plasma or EDTA plasma samples are available in 20 minutes.  The assay offers a broad assay range of 7.6 – 147.8 ng/mL.

Hanjoon Ryu, CEO of MedTest, stated: “Historically, Vitamin D deficiency has been associated with bone diseases such as rickets and osteomalacia. Recent clinical studies suggest that Vitamin D deficiency is also associated with increases in cardiovascular disease, cancer and infection.  Measurement of 25-OH Vitamin D is necessary for aiding correct interpretations of a patient’s status and enables physicians to intervene to minimize these diseases. The addition of the 25-OH Vitamin D Assay to our BS-480 analyzer allows physicians and laboratories to easily offer this test without having to purchase a dedicated analyzer thereby increasing their productivity and utility of a general chemistry analyzer.”

About MedTest:  MedTest is a diagnostics company that provides automated, fast, and cost effective blood and urine testing solutions for diabetes, cardiovascular disease, drugs of abuse, pain management and wellness testing.  In June 2013, MedTest acquired Pointe Scientific, a company that has been developing, manufacturing and distributing clinical diagnostic products including clinical chemistry reagents and instruments in the United States and internationally since 1981.  In the fall of 2014, MedTest acquired Clinitox Diagnostix, a company that manufactures and supports drug confirmatory testing via Liquid Chromatography/Mass Spectrometry (LC/MS).

For additional information:

MedTest
Debbie Whitehair, MT(ASCP)SC
Vice President, Marketing
484.748.1603
dwhitehair@medtest.com
www.medtest.com

 

PR-M3111-05   04/16

PREV 1 2 3 4 5 6 7 8 9 10 NEXT